Tvardi Therapeutics to Participate in Upcoming Investor Conferences

HOUSTON--(BUSINESS WIRE)-- Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that the Company’s Management will participate in the Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways, being held Tuesday, May 27, 2025, and the Jefferies Global Healthcare Conference, being held June 3 – 5, 2025, in New York, NY.

Details are as follows:

Piper Sandler 3rd Annual Virtual Lung Symposium with ATS Takeaways
Format: Fireside Chat
Date: Tuesday, May 27, 2025
Time: 11:30 AM ET

Jefferies Global Healthcare Conference
Format: Corporate Presentation and Investor Meetings
Date: Wednesday, June 4, 2025
Time: 11:40 AM ET

The webcast of the Jefferies presentation will be accessible on the Tvardi Investors’ website. A replay of the webcast will be available for approximately 60 days following the conference.

About Tvardi Therapeutics

Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708). To learn more, please visit tvarditherapeutics.com or follow us on LinkedIn and X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20250520914596/en/

For Tvardi:
Tvardi Investor Relations
[email protected]

PJ Kelleher
LifeSci Advisors
617-430-7579
[email protected]

Source: Tvardi Therapeutics, Inc.

You May Also Be Interested In

• South African Food Science Leader Gunnar Sigge Begins Term as President of the Institute of Food Technologists
• TRON H1 2026 Strategy Report: Anchored by DeFi, Driven by AI to Lead Crypto's Next Cycle
• MemoryDriver Relaunches Sept. 15 With a National "Beat the Clock" Navigation Challenge